NCT06771271

A Study to Investigate RO7200220 as Monotherapy and in Combination With Ranibizumab in Participants With Diabetic and Uveitic Macular Edema

A Multi-center, Non-Randomized, Open-label, Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7200220 in Monotherapy and in Combination With Ranibizumab Following Intravitreal Administration in Patients With Diabetic or Uveitic Macular Edema

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 85 (actual)
• Sponsor: Hoffmann-La Roche · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study was to assess the safety and tolerability of RO7200220 as monotherapy (diabetic macular edema \[DME\] or uveitic macular edema \[UME\] population) and in combination with ranibizumab (DME population only).

Conditions

• Diabetic Macular Edema
• Uveitic Macular Edema

Interventions

Type	Name	Description
DRUG	RO7200220	RO7200220 was administered as IVT injection.
DRUG	Ranibizumab	Ranibizumab was administered as IVT injection.

Timeline

• Start date: 2019-07-22
• Primary completion: 2023-11-13
• Completion: 2023-11-13
• First posted: 2025-01-13
• Last updated: 2025-01-13

Locations

19 sites across 1 country: United States

Regulatory

• FDA-regulated drug study